Last reviewed · How we verify
Placebo pill plus treatment as usual
A placebo pill combined with standard clinical care serves as a control comparator to measure the additional benefit of investigational treatment beyond baseline therapy.
The Placebo pill plus treatment as usual, marketed by the University of Chile, holds a unique position in the therapeutic landscape, leveraging existing treatments with an added placebo effect. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity. The primary risk is the lack of a distinct mechanism or primary indication, which may limit its appeal against more targeted therapies.
At a glance
| Generic name | Placebo pill plus treatment as usual |
|---|---|
| Sponsor | University of Chile |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a control arm used in clinical trials, not an active pharmaceutical intervention. The placebo pill itself has no pharmacological mechanism; it functions as an inert comparator while patients continue their usual standard-of-care treatment. This design allows researchers to isolate the true therapeutic effect of an experimental drug by comparing it against the natural disease course plus existing management.
Approved indications
Common side effects
Key clinical trials
- Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy (NA)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- Open-Label Placebo for Non-Specific Pain in the ED (NA)
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (PHASE2)
- Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation (NA)
- Mechanisms of Open and Hidden Placebo in Stroke Recovery (NA)
- Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity (PHASE4)
- The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo pill plus treatment as usual CI brief — competitive landscape report
- Placebo pill plus treatment as usual updates RSS · CI watch RSS
- University of Chile portfolio CI